Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study

[1]  N. Probst-Hensch,et al.  IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai , 2001, British Journal of Cancer.

[2]  R. Doll,et al.  Cancer Incidence and Mortality in England and Wales: Trends and Risk Factors , 2001 .

[3]  S. Hankinson,et al.  Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  K. Wheatley,et al.  Association between premature mortality and hypopituitarism , 2001, The Lancet.

[5]  C. Potten,et al.  High‐risk colorectal adenomas and serum insulin‐like growth factors , 2001, The British journal of surgery.

[6]  E. Riboli,et al.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.

[7]  J. Kleibeuker,et al.  One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults , 2000, Clinical endocrinology.

[8]  W. Willett,et al.  A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[10]  K. Fujieda,et al.  Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. , 1999, The Journal of clinical endocrinology and metabolism.

[11]  A. Renehan,et al.  Diversion colitis: a trigger for ulcerative colitis in the instream colon , 1999, Gut.

[12]  R. McNally,et al.  Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study , 1998 .

[13]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[14]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[15]  D. Leroith,et al.  Growth hormone treatment induces mammary gland hyperplasia in aging primates , 1997, Nature Medicine.

[16]  D. Graves,et al.  Risk of leukemia in children treated with human growth hormone: review and reanalysis. , 1997, The Journal of pediatrics.

[17]  T. Richards,et al.  Acromegaly, colonic polyps and carcinoma , 1997, Clinical endocrinology.

[18]  D. Graves,et al.  Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. , 1996, The Journal of clinical endocrinology and metabolism.

[19]  A. Cats,et al.  Increased epithelial cell proliferation in the colon of patients with acromegaly. , 1996, Cancer research.

[20]  A. Rundle,et al.  Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. , 1995, The Journal of clinical endocrinology and metabolism.

[21]  P. Amstad,et al.  Blockade of the insulin‐like growth‐factor‐I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF‐II‐mediated autocrine loop , 1994, International journal of cancer.

[22]  N. Skakkebaek,et al.  Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. , 1994, European journal of endocrinology.

[23]  N. Skakkebaek,et al.  The ratio between serum levels of insulin‐like growth factor (IGF)‐I and the IGF binding proteins (IGFBP‐1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients , 1994, Clinical endocrinology.

[24]  D. Wysowski,et al.  Risk of leukemia after treatment with pituitary growth hormone. , 1993, JAMA.

[25]  J. Fraumeni,et al.  Acromegaly and gastrointestinal cancer , 1991, Cancer.

[26]  M. Preece,et al.  Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. , 1991, BMJ.

[27]  B. Bengtsson,et al.  Premature mortality due to cardiovascular disease in hypopituitarism , 1990, The Lancet.

[28]  E. Ron,et al.  Gastrointestinal tumors in acromegalic patients. , 1985, The American journal of gastroenterology.

[29]  M. Raben.  Treatment of a pituitary dwarf with human growth hormone. , 1958, The Journal of clinical endocrinology and metabolism.

[30]  B. Schneider.  MANUAL of the international statistical classification of diseases, injuries, and causes of death. Addendum 1. Supplementary interpretations and instructions for coding causes of death. , 1953, Bulletin of the World Health Organization. Supplement.

[31]  A. Ogilvy-Stuart.  Safety of growth hormone after treatment of a childhood malignancy. , 1995, Hormone research.

[32]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.